Page last updated: 2024-11-02

pioglitazone and Atrial Fibrillation

pioglitazone has been researched along with Atrial Fibrillation in 12 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.

Research Excerpts

ExcerptRelevanceReference
"This study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects."9.19Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients. ( Liu, B; Wang, G; Wang, J, 2014)
" We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits."7.85Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Korantzopoulos, P; Li, G; Li, J; Liu, C; Liu, R; Liu, T; Tse, G; Wang, X, 2017)
"The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals."7.77Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011)
"Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses."7.74Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008)
"All patients had a history of type 2 diabetes mellitus (T2DM) and were divided based on whether they received pioglitazone before ablation or not."6.76Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. ( Gu, J; Jiang, W; Liu, X; Shi, H; Tan, H; Wang, X; Wang, Y; Zhou, L, 2011)
"Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK."5.38PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012)
"This study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects."5.19Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients. ( Liu, B; Wang, G; Wang, J, 2014)
" Pioglitazone (an oral hypoglycemic agent of the thiazolidinedione drug class) was shown in the IRIS trial to reduce the risk of recurrent stroke in patients with impaired glucose tolerance who had not developed type 2 diabetes mellitus."4.98Updates in Stroke Treatment. ( Mac Grory, B; Yaghi, S, 2018)
" We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits."3.85Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Korantzopoulos, P; Li, G; Li, J; Liu, C; Liu, R; Liu, T; Tse, G; Wang, X, 2017)
"The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals."3.77Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011)
"Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses."3.74Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008)
"All patients had a history of type 2 diabetes mellitus (T2DM) and were divided based on whether they received pioglitazone before ablation or not."2.76Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. ( Gu, J; Jiang, W; Liu, X; Shi, H; Tan, H; Wang, X; Wang, Y; Zhou, L, 2011)
"Treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, resulted in attenuation of pressure overload-induced LA fibrosis."2.48Novel strategy to prevent atrial fibrosis and fibrillation. ( Fukunaga, N; Hara, M; Kume, O; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O, 2012)
"Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK."1.38PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's9 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, C2
Liu, R1
Fu, H1
Li, J1
Wang, X2
Cheng, L1
Korantzopoulos, P2
Tse, G1
Li, G3
Liu, T3
Mac Grory, B1
Yaghi, S1
Liu, B1
Wang, J1
Wang, G1
Kume, O2
Takahashi, N2
Wakisaka, O2
Nagano-Torigoe, Y1
Teshima, Y2
Nakagawa, M1
Yufu, K1
Hara, M2
Saikawa, T2
Yoshimatsu, H1
Duffy, HS1
Gu, J2
Liu, X1
Shi, H1
Tan, H1
Zhou, L1
Jiang, W1
Wang, Y1
Xu, D1
Murakoshi, N1
Igarashi, M1
Hirayama, A1
Ito, Y1
Seo, Y1
Tada, H1
Aonuma, K1
Fukunaga, N1
Shimano, M1
Tsuji, Y1
Inden, Y1
Kitamura, K1
Uchikawa, T1
Harata, S1
Nattel, S1
Murohara, T1
Wilson, LD1
Tsai, CT1
Goudevenos, JA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Combination Therapy With Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction[NCT03794518]Phase 3648 participants (Anticipated)Interventional2019-03-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for pioglitazone and Atrial Fibrillation

ArticleYear
Updates in Stroke Treatment.
    Rhode Island medical journal (2013), 2018, 03-01, Volume: 101, Issue:2

    Topics: Acute Disease; Atrial Fibrillation; Brain Ischemia; Glucose Intolerance; Humans; Hypoglycemic Agents

2018
Novel strategy to prevent atrial fibrosis and fibrillation.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:10

    Topics: Animals; Antioxidants; Atrial Fibrillation; Chemokine CCL2; Disease Models, Animal; Endothelial Cell

2012

Trials

2 trials available for pioglitazone and Atrial Fibrillation

ArticleYear
Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients.
    International heart journal, 2014, Volume: 55, Issue:6

    Topics: Aged; Angiotensin II; Atrial Fibrillation; Diabetes Complications; Disease Progression; Double-Blind

2014
Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:9

    Topics: Aged; Atrial Fibrillation; Catheter Ablation; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies;

2011

Other Studies

8 other studies available for pioglitazone and Atrial Fibrillation

ArticleYear
Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits.
    Cardiovascular therapeutics, 2017, Volume: 35, Issue:5

    Topics: Action Potentials; Alloxan; Animals; Atrial Fibrillation; Atrial Remodeling; Diabetes Mellitus, Expe

2017
Pioglitazone may offer therapeutic advantages in diabetes-related atrial fibrillation.
    International journal of cardiology, 2013, Sep-30, Volume: 168, Issue:2

    Topics: Atrial Fibrillation; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinedione

2013
Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.
    Heart rhythm, 2011, Volume: 8, Issue:2

    Topics: Administration, Oral; Animals; Atrial Fibrillation; Blotting, Western; Disease Models, Animal; Echoc

2011
Inflammatory responses in the atria: should they stay or should they go?
    Heart rhythm, 2011, Volume: 8, Issue:2

    Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Fibrosis; Heart Atria; Inflammation; Inflammat

2011
PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model.
    Journal of cardiovascular electrophysiology, 2012, Volume: 23, Issue:2

    Topics: Aging; Animals; Antioxidants; Apoptosis; Atrial Fibrillation; Cardiotonic Agents; Disease Models, An

2012
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
    Heart rhythm, 2008, Volume: 5, Issue:3

    Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimi

2008
Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
    Heart rhythm, 2008, Volume: 5, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Comp

2008
Role of pioglitazone treatment on atrial remodeling and atrial fibrillation (AF)promotion in an experimental model of congestive heart failure.
    Heart rhythm, 2008, Volume: 5, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Heart

2008